Volume 8 Issue 11, Nov 2023

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)

Volume 8 Issue 11, Nov 2023:
Article
SARS-CoV-2 spike-specific TFH cells exhibit unique responses in infected and vaccinated individuals
Rongzhang He,Xingyu Zheng,Jian Zhang,Bo Liu,Qijie Wang,Qian Wu,Ziyan Liu,Fangfang Chang,Yabin Hu,Ting Xie,Yongchen Liu,Jun Chen,Jing Yang,Shishan Teng,Rui Lu,Dong Pan,You Wang,Liting Peng,Weijin Huang  ORCID: orcid.org/0000-0002-4246-8889,Velislava Terzieva  ORCID: orcid.org/0000-0002-3782-5917,Wenpei Liu,Youchun Wang  ORCID: orcid.org/0000-0001-9769-5141,Yi-Ping Li  ORCID: orcid.org/0000-0001-6011-3101 &…Xiaowang Qu  ORCID: orcid.org/0000-0002-8135-7292 
Long-term humoral immunity to SARS-CoV-2 is essential for preventing reinfection. The production of neutralizing antibody (nAb) and B cell differentiation are tightly regulated by T follicular help (TFH) cells. However, the longevity and functional role of TFH cell subsets in COVID-19 convalescents and vaccine recipients remain poorly defined. Here, we show that SARS-CoV-2 infection and inactivated vaccine elicited both spike-specific CXCR3+ TFH cell and CXCR3− TFH cell responses, which showed distinct response patterns. Spike-specific CXCR3+ TFH cells exhibit a dominant and more durable response than CXCR3− TFH cells that positively correlated with antibody responses. A third booster dose preferentially expands the spike-specific CXCR3+ TFH cell subset induced by two doses of inactivated vaccine, contributing to antibody maturation and potency. Functionally, spike-specific CXCR3+ TFH cells have a greater ability to induce spike-specific antibody secreting cells (ASCs) differentiation compared to spike-specific CXCR3− TFH cells. In conclusion, the persistent and functional role of spike-specific CXCR3+ TFH cells following SARS-CoV-2 infection and vaccination may play an important role in antibody maintenance and recall response, thereby conferring long-term protection. The findings from this study will inform the development of SARS-CoV-2 vaccines aiming to induce long-term protective immune memory.